

TENET HEALTHCARE CORP  
Form 8-K  
May 31, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 30, 2013**

**TENET HEALTHCARE CORPORATION**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction of  
incorporation)

**1-7293**  
(Commission File Number)

**95-2557091**  
(IRS Employer Identification No.)

**1445 Ross Avenue, Suite 1400, Dallas, Texas**  
(Address of principal executive offices)

**75202**  
(Zip Code)

Registrant's telephone number, including area code: **(469) 893-2200**

**Not Applicable**

Former name or former address, if changed since last report.)

## Edgar Filing: TENET HEALTHCARE CORP - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-



and April 2012, 4.75% senior secured notes due 2020, which were issued in October 2012, and 4.50% senior secured notes due 2021, which were issued in February 2013, and similarly will be guaranteed by and secured by a pledge of the capital stock and other ownership interests of certain of Tenet's subsidiaries, and will be subordinated to Tenet's obligations under its senior secured revolving credit facility, and any of its subsidiaries' secured guarantees thereof, to the extent of the value of the collateral securing borrowings under such facility.

The 2021 Notes were issued pursuant to the Base Indenture, as supplemented by a twentieth supplemental indenture (the Twentieth Supplemental Indenture) dated May 30, 2013, among Tenet, certain of its subsidiaries that will act as guarantors thereunder and The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York. The Twentieth Supplemental Indenture contains covenants that, among other things, restrict Tenet's ability and the ability of its subsidiaries: to incur liens; provide subsidiary guarantees; consummate asset sales; enter into sale and lease-back transactions; or consolidate, merge or sell all or substantially all of their assets, other than in certain transactions between one or more of Tenet's wholly owned subsidiaries and Tenet. These restrictions, however, are subject to a number of important exceptions and qualifications. In particular, there are no restrictions on Tenet's ability or the ability of its subsidiaries to incur additional indebtedness, make restricted payments, pay dividends or make distributions in respect of capital stock, purchase or redeem capital stock, enter into transactions with affiliates or make advances to, or invest in, other entities (including unaffiliated entities).

The Twentieth Supplemental Indenture also provides that the 2021 Notes may become subject to redemption under certain circumstances, including a change of control (as defined in the Twentieth Supplemental Indenture) of Tenet. In addition, Tenet may, at its option, redeem the 2021 Notes in whole or in part at any time at a redemption price equal to 100% of the principal amount of the 2021 Notes being redeemed plus the applicable make-whole premium set forth in the Twentieth Supplemental Indenture, together with accrued and unpaid interest.

In connection with the issuance of the 2021 Notes, Tenet also entered into an Exchange and Registration Rights Agreement, dated as of May 30, 2013 (the Registration Rights Agreement), with Barclays Capital Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global Markets Inc. and Wells Fargo Securities, LLC, as representatives of the initial purchasers named therein. Pursuant to the Registration Rights Agreement, Tenet has agreed to use commercially reasonable efforts to register the 2021 Notes with the Securities and Exchange Commission if the 2021 Notes have not become freely tradable (as defined in the agreement) on or before the 380th day following the date hereof.

The foregoing is a summary and is qualified by reference to the Twentieth Supplemental Indenture and the Registration Rights Agreement, which are filed herewith as Exhibits 4.1 and 10.1, respectively, and are incorporated herein by reference.

**Item 8.01**                      **Other Events**

On May 30, 2013, Tenet issued a press release announcing (1) the completion of the private offering and the issuance of the 2021 Notes and (2) the early tender results and initial settlement of its previously announced cash tender offer and consent solicitation for its outstanding 2019 Notes.

For additional information, reference is made to the press release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01**                      **Financial Statements and Exhibits**

(d)                      The following exhibits are filed as a part of this Report.

<b>Exhibit No.</b>	<b>Description</b>
4.1	Twentieth Supplemental Indenture dated as of May 30, 2013 among Tenet, certain of its subsidiaries and The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York.
4.2	Twenty-First Supplemental Indenture dated as of May 30, 2013 among Tenet, certain of its subsidiaries and The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York.
10.1	Exchange and Registration Rights Agreement dated as of May 30, 2013, by and among Tenet, certain of its subsidiaries, Barclays Capital Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global Markets Inc. and Wells Fargo Securities, LLC, as representatives of the initial purchasers named therein.
99.1	Press release issued on May 30, 2013, announcing the completion of a private offering of senior secured notes due 2021 and Tenet's early results and initial settlement of its tender offer and consent solicitation for its senior secured notes due 2019.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TENET HEALTHCARE CORPORATION,

Date: May 30, 2013

By:	/s/ Paul A. Castanon	
	Name:	Paul A. Castanon
	Title:	Vice President, Deputy General Counsel and Corporate Secretary

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
4.1	Twentieth Supplemental Indenture dated as of May 30, 2013 among Tenet, certain of its subsidiaries and The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York.
4.2	Twenty-First Supplemental Indenture dated as of May 30, 2013 among Tenet, certain of its subsidiaries and The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York.
10.1	Exchange and Registration Rights Agreement dated as of May 30, 2013, by and among Tenet, certain of its subsidiaries, Barclays Capital Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global Markets Inc. and Wells Fargo Securities, LLC, as representatives of the initial purchasers named therein.
99.1	Press release issued on May 30, 2013, announcing the completion of a private offering of senior secured notes due 2021 and Tenet's early results and initial settlement of its tender offer and consent solicitation for its senior secured notes due 2019.